Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, Patmore R, Pettengell R, Ardeshna KM, Lawrie A, Montoto S, Paneesha S, Clifton-Hadley L, Linch DC. McMillan AK, et al. Among authors: linch dc. Ann Oncol. 2020 Sep;31(9):1251-1259. doi: 10.1016/j.annonc.2020.05.016. Epub 2020 May 26. Ann Oncol. 2020. PMID: 32464282 Free PMC article. Clinical Trial.
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Gleeson M, Counsell N, Cunningham D, Lawrie A, Clifton-Hadley L, Hawkes E, McMillan A, Ardeshna KM, Burton C, Chadwick N, Gambell J, Smith P, Mouncey P, Pocock C, Radford J, Davies J, Turner D, Kruger A, Johnson P, Linch D. Gleeson M, et al. Br J Haematol. 2021 Mar;192(6):1015-1019. doi: 10.1111/bjh.16691. Epub 2020 May 20. Br J Haematol. 2021. PMID: 32436212 Free article. Clinical Trial.
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.
Phillips EH, Burton C, Kirkwood AA, Barrans S, Lawrie A, Rule S, Patmore R, Pettengell R, Ardeshna KM, Montoto S, Paneesha S, Clifton-Hadley L, Linch DC, McMillan AK. Phillips EH, et al. Among authors: linch dc. EJHaem. 2020 Apr 29;1(1):133-141. doi: 10.1002/jha2.3. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847742 Free PMC article.
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Kühnl A, et al. Ann Oncol. 2017 Jul 1;28(7):1540-1546. doi: 10.1093/annonc/mdx128. Ann Oncol. 2017. PMID: 28398499 Free PMC article. Clinical Trial.
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, McMillan A, Ardeshna KM, Jack A, Smith P, Mouncey P, Pocock C, Radford JA, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Gleeson M, et al. Ann Oncol. 2017 Oct 1;28(10):2511-2516. doi: 10.1093/annonc/mdx353. Ann Oncol. 2017. PMID: 28961838 Free PMC article. Clinical Trial.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Cunningham D, et al. Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22. Lancet. 2013. PMID: 23615461 Free article. Clinical Trial.
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. Rule S, et al. Haematologica. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26. Haematologica. 2016. PMID: 26611473 Free PMC article. Clinical Trial.
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Gleeson M, Hawkes EA, Cunningham D, Chadwick N, Counsell N, Lawrie A, Jack A, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Linch D. Gleeson M, et al. Br J Haematol. 2016 Nov;175(4):668-672. doi: 10.1111/bjh.14287. Epub 2016 Aug 1. Br J Haematol. 2016. PMID: 27477167 Free article.
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
Townsend W, Leong S, Hoskin P, Diez P, Patrick P, Linch D, Wong WL, Kayani I, Sanghera B, Lopes A, Daw S, Collins G, Clifton-Hadley L, Ardeshna K. Townsend W, et al. Br J Haematol. 2020 Apr;189(1):128-132. doi: 10.1111/bjh.16296. Epub 2019 Nov 11. Br J Haematol. 2020. PMID: 31710702 Free PMC article. Clinical Trial.
506 results